Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cumberland Pharmaceuticals (CPIX) EBT Margin (2016 - 2025)

Historic EBT Margin for Cumberland Pharmaceuticals (CPIX) over the last 17 years, with Q3 2025 value amounting to 23.44%.

  • Cumberland Pharmaceuticals' EBT Margin fell 66500.0% to 23.44% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.18%, marking a year-over-year increase of 211400.0%. This contributed to the annual value of 17.08% for FY2024, which is 11900.0% down from last year.
  • Latest data reveals that Cumberland Pharmaceuticals reported EBT Margin of 23.44% as of Q3 2025, which was down 66500.0% from 6.73% recorded in Q2 2025.
  • Cumberland Pharmaceuticals' 5-year EBT Margin high stood at 10.7% for Q1 2025, and its period low was 67.11% during Q4 2023.
  • For the 5-year period, Cumberland Pharmaceuticals' EBT Margin averaged around 14.69%, with its median value being 12.49% (2022).
  • As far as peak fluctuations go, Cumberland Pharmaceuticals' EBT Margin crashed by -406800bps in 2023, and later skyrocketed by 483400bps in 2024.
  • Quarter analysis of 5 years shows Cumberland Pharmaceuticals' EBT Margin stood at 52.59% in 2021, then soared by 50bps to 26.43% in 2022, then crashed by -154bps to 67.11% in 2023, then surged by 72bps to 18.77% in 2024, then fell by -25bps to 23.44% in 2025.
  • Its EBT Margin was 23.44% in Q3 2025, compared to 6.73% in Q2 2025 and 10.7% in Q1 2025.